Enhancement of inhibitory neurotransmission by GABAA receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism

Neuron

Volumn 81, Issue 6, 2014, Pages 1282-1289

  Han, Sung ^a   Tai, Chao ^a   Jones, Christina J ^a   Scheuer, Todd ^a   Catterall, William A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; CLONAZEPAM; L 838 417; UNCLASSIFIED DRUG; ZOLPIDEM; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; FLUOROBENZENE; L 838,417; PROTEIN SUBUNIT; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; BENZODIAZEPINE; POSTSYNAPTIC RECEPTOR;

ADULT; ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BEHAVIOR DISORDER; COGNITIVE DEFECT; COMPULSION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXPERIMENTAL MODEL; GABAERGIC TRANSMISSION; LOW DRUG DOSE; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; SPATIAL LEARNING; SYNAPTIC INHIBITION; 129 MOUSE; ANIMAL; ANIMAL BEHAVIOR; AUTISTIC DISORDER; BRAIN; C57BL MOUSE; DRUG EFFECTS; HUMAN RELATION; METABOLISM; PROTEIN SUBUNIT; SOCIAL BEHAVIOR; SYNAPTIC TRANSMISSION; ANIMAL TISSUE; DRUG EFFECT; INHIBITORY POSTSYNAPTIC POTENTIAL; MOUSE MODEL; NERVE CELL INHIBITION; NEUROMODULATION; WILD TYPE;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BRAIN; DISEASE MODELS, ANIMAL; FLUOROBENZENES; INTERPERSONAL RELATIONS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; PROTEIN SUBUNITS; PYRIDINES; RECEPTORS, GABA-A; SOCIAL BEHAVIOR; SYNAPTIC TRANSMISSION; TRIAZOLES;

EID: 84896279364     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.01.016     Document Type: Article

References (39)

1. Abrahams B.S., Geschwind D.H. Advances in autism genetics: on the threshold of a new neurobiology. Nat. Rev. Genet. 2008, 9:341-355.
2. Auerbach B.D., Osterweil E.K., Bear M.F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011, 480:63-68.
3. Bateson A.N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr. Pharm. Des. 2002, 8:5-21.
4. Berry-Kravis E.M., Hessl D., Rathmell B., Zarevics P., Cherubini M., Walton-Bowen K., Mu Y., Nguyen D.V., Gonzalez-Heydrich J., Wang P.P., et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 2012, 4:ra127.
5. Chao H.T., Chen H., Samaco R.C., Xue M., Chahrour M., Yoo J., Neul J.L., Gong S., Lu H.C., Heintz N., et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010, 468:263-269.
6. Defensor E.B., Pearson B.L., Pobbe R.L., Bolivar V.J., Blanchard D.C., Blanchard R.J. A novel social proximity test suggests patterns of social avoidance and gaze aversion-like behavior in BTBR T+ tf/J mice. Behav. Brain Res. 2011, 217:302-308.
7. Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986, 27(Suppl 1):S45-S52.
8. Fritschy J.M., Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J.Comp. Neurol. 1995, 359:154-194.
9. Galpern W.R., Lumpkin M., Greenblatt D.J., Shader R.I., Miller L.G. Chronic benzodiazepine administration. VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration. Psychopharmacology (Berl.) 1991, 104:225-230.
10. Gandal M.J., Sisti J., Klook K., Ortinski P.I., Leitman V., Liang Y., Thieu T., Anderson R., Pierce R.C., Jonak G., et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transcult. Psychiatry 2012, 2:e142.
11. Gatto C.L., Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front. Synaptic Neurosci. 2010, 2:4.
12. Geschwind D.H. Genetics of autism spectrum disorders. Trends Cogn. Sci. 2011, 15:409-416.
13. +/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 2012, 489:385-390.
14. Harmar A.J., Hills R.A., Rosser E.M., Jones M., Buneman O.P., Dunbar D.R., Greenhill S.D., Hale V.A., Sharman J.L., Bonner T.I., et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res. 2009, 37(Database issue):D680-D685.
15. Henderson C., Wijetunge L., Kinoshita M.N., Shumway M., Hammond R.S., Postma F.R., Brynczka C., Rush R., Thomas A., Paylor R., et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 2012, 4:ra128.
16. + tf/J mouse model of autism. PLoS ONE 2013, 8:e61829.
17. Li X., Zou H., Brown W.T. Genes associated with autism spectrum disorder. Brain Res. Bull. 2012, 88:543-552.
18. Löscher W., Rundfeldt C., Hönack D., Ebert U. Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clonazepam, clobazam and abecarnil. J.Pharmacol. Exp. Ther. 1996, 279:561-572.
19. Löw K., Crestani F., Keist R., Benke D., Brünig I., Benson J.A., Fritschy J.M., Rülicke T., Bluethmann H., Möhler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290:131-134.
20. MacPherson P., McGaffigan R., Wahlsten D., Nguyen P.V. Impaired fear memory, altered object memory and modified hippocampal synaptic plasticity in split-brain mice. Brain Res. 2008, 1210:179-188.
21. Markram K., Markram H. The intense world theory - a unifying theory of the neurobiology of autism. Front. Hum. Neurosci. 2010, 4:224.
22. Mathiasen L.S., Mirza N.R., Rodgers R.J. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and zolpidem on anxiety-like behaviours in laboratory mice. Pharmacol. Biochem. Behav. 2008, 90:19-36.
23. McFarlane H.G., Kusek G.K., Yang M., Phoenix J.L., Bolivar V.J., Crawley J.N. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav. 2008, 7:152-163.
24. Michalon A., Sidorov M., Ballard T.M., Ozmen L., Spooren W., Wettstein J.G., Jaeschke G., Bear M.F., Lindemann L. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012, 74:49-56.
25. Peça J., Feliciano C., Ting J.T., Wang W., Wells M.F., Venkatraman T.N., Lascola C.D., Fu Z., Feng G. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 2011, 472:437-442.
26. Peñagarikano O., Abrahams B.S., Herman E.I., Winden K.D., Gdalyahu A., Dong H., Sonnenblick L.I., Gruver R., Almajano J., Bragin A., et al. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 2011, 147:235-246.
27. Prenosil G.A., Schneider Gasser E.M., Rudolph U., Keist R., Fritschy J.M., Vogt K.E. Specific subtypes of GABAA receptors mediate phasicand tonic forms of inhibition in hippocampal pyramidal neurons. J.Neurophysiol. 2006, 96:846-857.
28. Rovira C., Ben-Ari Y. Developmental study of benzodiazepine effects on monosynaptic GABAA-mediated IPSPs of rat hippocampal neurons. J.Neurophysiol. 1993, 70:1076-1085.
29. Rubenstein J.L., Merzenich M.M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003, 2:255-267.
30. Rudolph U., Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 2011, 10:685-697.
31. Rudolph U., Möhler H. Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu. Rev. Pharmacol. Toxicol. 2004, 44:475-498.
32. Savić M.M., Obradović D.I., Ugresić N.D., Cook J.M., Yin W., Bokonjić D.R. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol. Biochem. Behav. 2004, 79:279-290.
33. Savić M.M., Obradović D.I., Ugresić N.D., Cook J.M., Yin W., Van Linn M., Bokonjić D.R. Benzodiazepine site inverse agonists and locomotor activity in rats: bimodal and biphasic influence. Pharmacol. Biochem. Behav. 2006, 84:35-42.
34. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol. Rev. 1995, 47:181-234.
35. Smith G.B., Olsen R.W. Functional domains of GABAA receptors. Trends Pharmacol. Sci. 1995, 16:162-168.
36. A receptor α subunits differentially contribute to diazepam tolerance after chronic treatment. PLoS ONE 2012, 7:e43054.
37. Yang M., Abrams D.N., Zhang J.Y., Weber M.D., Katz A.M., Clarke A.M., Silverman J.L., Crawley J.N. Low sociability in BTBR T+tf/J mice is independent of partner strain. Physiol. Behav. 2012, 107:649-662.
38. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., Sohal V.S., Goshen I., Finkelstein J., Paz J.T., et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477:171-178.
39. Zoghbi H.Y., Bear M.F. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 2012, 4:4.